NYUCT Design Labs launches Edible Ventures, a first-of-its-kind, full stack design and development cell for food & restaurant brands
MUMBAI, India, March 19, 2026 /PRNewswire/ -- NYUCT Design Labs, India's first…
REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing ServicesBELTSVILLE, Md.,…
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet in the treatment of canine mast cell tumors
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS…
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader…
MEDEZE Receives Frost & Sullivan’s 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence…
Cell Impact to deliver tool to leading automotive manufacturer
KARLSKOGA, Sweden, Dec. 9, 2025 /PRNewswire/ -- Cell Impact has signed an agreement…
Miltenyi Biotec Receives ‘Special Recognition Award’ for Pioneering Work in Cell & Gene Therapy at BioSpectrum India Excellence Awards 2025
NEW DELHI, Dec. 9, 2025 /PRNewswire/ -- Miltenyi Biotec has been honoured…
Xcell Biosciences and Culture Biosciences Partner to Advance Cell Therapy Quality Through AI and Machine Learning
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Xcell…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of…
